Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. Journal of thrombosis and haemostasis : JTH. [J Thromb Haemost] Journal article | | Title | Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. | | Author(s) | Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, Kälebo P, ODIXa-HIP Study Investigators | | Institution | Sahlgrenska University HospitalOstra, Gothenburg, Sweden. b.eriksson@orthop.gu.se | | Source | J Thromb Haemost 2006 Jan; 4(1):121-8. | | MeSH | Adult
Aged
Aged, 80 and over
Anticoagulants
Arthroplasty, Replacement, Hip
Dose-Response Relationship, Drug
Double-Blind Method
Enoxaparin
Factor Xa
Female
Hemorrhage
Humans
Male
Middle Aged
Morpholines
Postoperative Complications
Pulmonary Embolism
Research Support, Non-U.S. Gov't
Thiophenes
Thromboembolism
Venous Thrombosis
| | Abstract | BACKGROUND: Joint replacement surgery is an appropriate model for dose-ranging studies investigating new anticoagulants.
OBJECTIVES: To assess the efficacy and safety of a novel, oral, direct factor Xa (FXa) inhibitor--BAY 59-7939--relative to enoxaparin in patients undergoing elective total hip replacement.
METHODS: In this double-blind, double-dummy, dose-ranging study, patients were randomized to oral BAY 59-7939 (2.5, 5, 10, 20, or 30 mg b.i.d.), starting 6-8 h after surgery, or s.c. enoxaparin 40 mg once daily, starting on the evening before surgery. Treatment was continued until mandatory bilateral venography was performed 5-9 days after surgery.
RESULTS: Of 706 patients treated, 548 were eligible for the primary efficacy analysis. The primary efficacy endpoint was the incidence of any deep vein thrombosis, non-fatal pulmonary embolism, and all-cause mortality; rates were 15%, 14%, 12%, 18%, and 7% for BAY 59-7939 2.5, 5, 10, 20, and 30 mg b.i.d., respectively, compared with 17% for enoxaparin. The primary efficacy analysis did not demonstrate any significant trend in dose-response relationship for BAY 59-7939. The primary safety endpoint was major, postoperative bleeding; there was a significant increase in the frequency of events with increasing doses of BAY 59-7939 (P = 0.045), but no significant differences between individual BAY 59-7939 doses and enoxaparin.
CONCLUSIONS: When efficacy and safety were considered together, the oral, direct FXa inhibitor BAY 59-7939, at 2.5-10 mg b.i.d., compared favorably with enoxaparin for the prevention of venous thromboembolism in patients undergoing elective total hip replacement. | | Language | eng | | Pub Type(s) | Journal Article
Multicenter Study
Randomized Controlled Trial
| | PubMed ID | 16409461 |
|
|
| |
Advertise on this site.
| | |
|
